The collection of Chinese medicine pieces is like an arrow, and quality has become the first barrier for pharmaceutical enterprises to enter the market

【Pharmaceutical Network Market Analysis】Judging from public information, recently, from the national level, to Anhui, Shaanxi, Fujian, Heilongjiang and other places, there have been unqualified problems of traditional Chinese medicine pieces, and fines ranging from tens of thousands to hundreds of thousands of yuan have been eaten, which has once again attracted the attention of the
industry.
On September 15, the NMPA issued a notice on 17 batches of drugs that did not meet the regulations, including 8 batches of chrysanthemums, 1 batch of madder and 4 batches of comfrey
.
At the local level, such as recent news, the vinegar myrrh produced and sold by a certain drinking chip company in Anhui Province was inspected by the Ninghe Drug Inspection Institute of Tianjin Drug Control Institute and did not meet the regulations, and the unqualified item was [inspection] acid insoluble ash
.
According to relevant regulations, the Anhui Provincial Food and Drug Administration fined and confiscated a total of more than 110,000 yuan
.
On September 30, the Shaanxi Provincial Food and Drug Administration issued the third phase of the drug quality announcement
in 2022.
According to the announcement, the Provincial Drug Administration recently organized drug regulatory departments at all levels in the province to carry out drug sampling
.
A total of 6 batches of substandard inferior drugs were investigated and dealt with in this random inspection, and the non-compliant items were mainly traits, inspections, content determination, leachables, etc.
, and there were 6 manufacturers labeled as unqualified products
.
On September 27, the Fujian Provincial Food and Drug Administration issued a drug quality sampling inspection announcement, the results of which showed that the products of 3 Chinese Medicine Pieces Co.
, Ltd.
were found to be non-compliant, and one of the companies had two varieties that failed to conform
.
In September, an administrative penalty released by the Anhui Provincial Food and Drug Administration showed that a traditional Chinese medicine piece company in Bozhou City was fined and confiscated by the Anhui Provincial Food and Drug Administration for producing and selling chrysanthemums that did
not comply with regulations.
Non-conforming items are [Check].

According to two administrative punishment notices issued by the Anhui Food and Drug Administration on February 10, two Chinese medicine pieces Co.
, Ltd.
in Anhui were required to suspend the production of Chinese medicine pieces because they found that the quality system could not operate effectively during the flight inspection and there were risks and hidden dangers in the quality and safety of Chinese medicine pieces, and at the same time, they were required to file a case for investigation and punishment
by the second branch of the provincial bureau according to law for relevant illegal clues found during the inspection.
On July 20, the Heilongjiang Provincial Food and Drug Administration issued an administrative penalty decision, in which a Heilongjiang Traditional Chinese Medicine Pieces Co.
, Ltd.
was punished for producing and selling inferior Chinese medicine pieces "Sea Wind Vine" without illegal income and warning
.
.
.
.
.
.
.
.
Traditional Chinese medicine pieces are one of the three pillars of China's traditional Chinese medicine industry, driven by the aging of the population and favorable policies, the industry has developed rapidly, but due to the backward standards of some medicinal materials, unscientific cultivation of traditional Chinese medicine, many small workshops with low prices and low quality, and the difficulty of precise supervision, the industry often has the problem
of unqualified product quality.
In order to improve the quality of Chinese medicine pieces, the state has continuously tightened the supervision of the Chinese medicine pieces industry, exposed substandard drugs, and increased penalties for relevant pharmaceutical enterprises
.
According to the 2021 National Blue Book of Chinese Medicine Regulation, in recent years, the control of APIs, production processes and product quality of Chinese medicine pieces have been greatly improved and improved, and from 2016 to 2021, the overall qualification rate of Chinese medicine pieces has increased from 77.
7% to 98.
4%.

At present, the collection of proprietary Chinese medicines and Chinese medicine pieces has been like an arrow
.
Not long ago, the "National Proprietary Chinese Medicine Alliance Procurement Announcement" was officially issued, and 30 provincial levels (excluding Hunan, Fujian, Hong Kong, Macao and Taiwan) will form the National Joint Procurement Office for Proprietary Chinese Medicines, led
by the Hubei Medical Insurance Bureau.
At the same time, various localities are also actively exploring provincial-level and inter-provincial alliance collective procurement
in the fields of traditional Chinese medicine pieces.
The industry believes that with the advancement of the centralized procurement policy, quality is the first hurdle for pharmaceutical companies to participate in the collective procurement of proprietary Chinese medicines and pieces of traditional Chinese medicine, and the strict supervision of relevant departments will promote the standardization and high-quality development of the industry, and the huge fines also remind relevant enterprises that only adhere to compliance is the way
out.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.